2,008 Shares in Alnylam Pharmaceuticals, Inc. $ALNY Acquired by Elm Partners Management LLC

Elm Partners Management LLC acquired a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 2,008 shares of the biopharmaceutical company’s stock, valued at approximately $798,000.

Several other hedge funds have also modified their holdings of ALNY. Brighton Jones LLC purchased a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter worth approximately $243,000. Geneos Wealth Management Inc. raised its holdings in shares of Alnylam Pharmaceuticals by 372.3% during the 1st quarter. Geneos Wealth Management Inc. now owns 222 shares of the biopharmaceutical company’s stock worth $60,000 after acquiring an additional 175 shares in the last quarter. Flow Traders U.S. LLC purchased a new stake in shares of Alnylam Pharmaceuticals during the 2nd quarter worth approximately $241,000. Daiwa Securities Group Inc. raised its holdings in shares of Alnylam Pharmaceuticals by 0.3% during the 2nd quarter. Daiwa Securities Group Inc. now owns 12,941 shares of the biopharmaceutical company’s stock worth $4,220,000 after acquiring an additional 35 shares in the last quarter. Finally, NewEdge Advisors LLC raised its holdings in shares of Alnylam Pharmaceuticals by 70,300.0% during the 2nd quarter. NewEdge Advisors LLC now owns 704 shares of the biopharmaceutical company’s stock worth $229,000 after acquiring an additional 703 shares in the last quarter. 92.97% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

ALNY has been the topic of several recent research reports. HC Wainwright reaffirmed a “buy” rating and set a $510.00 price objective on shares of Alnylam Pharmaceuticals in a report on Tuesday, May 5th. Citigroup initiated coverage on Alnylam Pharmaceuticals in a report on Tuesday, May 19th. They set a “buy” rating and a $380.00 price objective on the stock. Needham & Company LLC decreased their price objective on Alnylam Pharmaceuticals from $529.00 to $510.00 and set a “buy” rating on the stock in a report on Thursday, February 12th. Weiss Ratings upgraded Alnylam Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, May 4th. Finally, Freedom Capital upgraded Alnylam Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Tuesday, February 17th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat.com, Alnylam Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $463.13.

Alnylam Pharmaceuticals Stock Performance

NASDAQ:ALNY opened at $301.98 on Monday. The stock’s fifty day moving average is $309.38 and its 200 day moving average is $354.12. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $284.28 and a fifty-two week high of $495.55. The firm has a market capitalization of $40.32 billion, a PE ratio of 82.51 and a beta of 0.29. The company has a debt-to-equity ratio of 0.94, a quick ratio of 3.06 and a current ratio of 3.13.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.99 earnings per share for the quarter, beating the consensus estimate of $0.87 by $1.12. Alnylam Pharmaceuticals had a return on equity of 85.76% and a net margin of 11.72%.The company had revenue of $1.17 billion for the quarter, compared to analyst estimates of $1.12 billion. During the same quarter in the prior year, the firm posted ($0.44) EPS. Alnylam Pharmaceuticals’s quarterly revenue was up 96.4% compared to the same quarter last year. On average, sell-side analysts anticipate that Alnylam Pharmaceuticals, Inc. will post 7.36 earnings per share for the current year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, EVP Kevin Joseph Fitzgerald sold 1,652 shares of the company’s stock in a transaction on Tuesday, March 3rd. The stock was sold at an average price of $319.73, for a total value of $528,193.96. Following the transaction, the executive vice president owned 21,860 shares of the company’s stock, valued at $6,989,297.80. This represents a 7.03% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Pushkal Garg sold 1,775 shares of the company’s stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $319.74, for a total value of $567,538.50. Following the completion of the transaction, the executive vice president directly owned 23,406 shares in the company, valued at $7,483,834.44. This trade represents a 7.05% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 7,337 shares of company stock valued at $2,370,087 in the last quarter. 0.86% of the stock is owned by insiders.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.